within Pharmacolibrary.Drugs.S_SensoryOrgans.S01B_AntiinflammatoryAgents.S01BA13_Rimexolone;

model Rimexolone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.388888888888889e-08,
    adminDuration = 600,
    adminMass = 1 / 1000000,
    adminCount = 1,
    Vd = 5e-05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Rimexolone</td></tr><tr><td>ATC code:</td><td>S01BA13</td></tr><td>route:</td><td>ophthalmic</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.05</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.05</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Rimexolone is a synthetic corticosteroid with anti-inflammatory properties, primarily used as an ophthalmic suspension to treat post-operative eye inflammation and anterior uveitis. It is an FDA-approved medication but is now less commonly used due to the availability of alternatives.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic (PK) data for rimexolone after ophthalmic administration could be identified; parameter estimates below are theoretical or inferred based on class and administration route.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01BA13 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Rimexolone;
